SYMLIN Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Symlin, and what generic alternatives are available?

Symlin is a drug marketed by Astrazeneca Ab and is included in one NDA.

The generic ingredient in SYMLIN is pramlintide acetate. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pramlintide acetate profile page.

Summary for SYMLIN

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	11
Clinical Trials:	20
Patent Applications:	2,786
Drug Prices:	Drug price information for SYMLIN
DailyMed Link:	SYMLIN at DailyMed

Drug patent expirations by year for SYMLIN

Recent Clinical Trials for SYMLIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Aging (NIA)	Early Phase 1
Boston University	Early Phase 1
H. Lee Moffitt Cancer Center and Research Institute	Early Phase 1

See all SYMLIN clinical trials

Pharmacology for SYMLIN

Drug Class	Amylin Analog
Mechanism of Action	Amylin Agonists

Anatomical Therapeutic Chemical (ATC) Classes for SYMLIN

A10BX	Other blood glucose lowering drugs, excl. insulins
A10B	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10	DRUGS USED IN DIABETES
A	Alimentary tract and metabolism

US Patents and Regulatory Information for SYMLIN

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007		RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007		RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-001	Mar 16, 2005		DISCN	No	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for SYMLIN

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007	⤷ Try a Trial	⤷ Try a Trial
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007	⤷ Try a Trial	⤷ Try a Trial
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-003	Sep 25, 2007	⤷ Try a Trial	⤷ Try a Trial
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332-002	Sep 25, 2007	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for SYMLIN

See the table below for patents covering SYMLIN around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Canada	2077265		⤷ Try a Trial
Japan	S6463594	PEPTIDES	⤷ Try a Trial
World Intellectual Property Organization (WIPO)	9220366		⤷ Try a Trial
Japan	2003238594	NEW AMYLIN AGONIST PEPTIDE AND USE THEREFOR	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for SYMLIN

Recent Clinical Trials for SYMLIN

Pharmacology for SYMLIN

Anatomical Therapeutic Chemical (ATC) Classes for SYMLIN

Make Better Decisions: Try a trial or see plans & pricing